Do you want to read an article? Please log in or register.
Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study
Type 2 Diabetes
Related content
COMMENTED
Diabetes - General
Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Cardiovasc Diabetol
Lohia P, Kapur S, Benjaram S, Cantor Z, Mahabadi N, Mir T, Badr MS
doi: 10.1186/s12933-021-01336-0
COMMENTED
Lipids
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Lancet.
Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S
doi: 10.1016/S0140-
COMMENTED
Diabetes - General
Statin therapy for primary prevention in the elderly and its association with new-onset diabetes, cardiovascular events and all-cause mortality
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Am J Med
Lavie G, Hoshen M, Leibowitz M, Benis A, Akriv A, Balicer R, Reges O
doi: 10.1016/j.amjmed.2020.09.058
RECOMMENDED
Diabetes - GeneralType 2 DiabetesDiabetic ComplicationsGlycemic ControlObesity and Bariatric Surgery
Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study
Ann Intern Med.
O'Brien R, Johnson E, Haneuse S, Coleman KJ, O'Connor PJ, Fisher DP, Sidney S, Bogart A, Theis MK, Anau J, Schroeder EB, Arterburn D
doi: 10.7326/M17-2383.
Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke
Circulation.
Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K
doi: 10.1161/
COMMENTED
Type 2 Diabetes
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
Lancet Diabetes Endocrinol.
Svanström H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B
doi: 10.1016/S2213-
COMMENTED
Type 2 Diabetes
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Lancet.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS
doi: 10.1016/S0140-6736
COMMENTED
Thyroid
Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study
Lancet Diabetes Endocrinol.
Okosieme OE, Taylor PN, Evans C, Thayer D, Chai A, Khan I, Draman MS, Tennant B, Geen J, Sayers A, French R, Lazarus JH, Premawardhana LD,
Dayan CM
doi: 10.1016/S2213-8587(19)30059-2.
COMMENTED
Diabetes - GeneralType 2 DiabetesDiabetes and Pregnancy
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study
Diabetologia.
Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM; Diabetes Prevention Program Research Group
doi: 10.1007/s00125-017-4361-9.